Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05188508 · ClinicalTrials.gov registry record · Phase 2
Pembrolizumab, Olaparib, and Temozolomide for People With Glioma
A Phase 2 study of Glioma, sponsored by Memorial Sloan Kettering Cancer Center.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 57
- Enrollment target
- 10
- Study locations
NCT05188508: Recruiting Phase 2 study of Glioma, sponsored by Memorial Sloan Kettering Cancer Center.
NCT05188508 is a Phase 2 study of Glioma that is actively recruiting participants, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 57 participants, below the 209-participant average among 87 other Glioma trials with a reported enrollment target (73% lower). The trial reports 10 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05188508, a Phase 2 study of Glioma, is actively recruiting participants, sponsored by Memorial Sloan Kettering Cancer Center.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 57 participants
- Enrollment target
- 10
- Study locations
Study Summary
This study will test the safety and effectiveness of a combination of pembrolizumab, olaparib, and temozolomide to see how well these drugs work when given together in people with a glioma that either did not respond to previous treatment or came back after treatment.
Primary Outcome
The response will be determined as outlined in the RANO and iRANO.
Conditions Studied
Interventions
- DRUG Pembrolizumab
- COMBINATION_PRODUCT Olaparib and Temozolomide
Study Locations (10)
New York
- Memorial Sloan Kettering Suffolk -Commack (Limited Protocol Activities) - Commack
- Memorial Sloan Kettering Westchester (Limited Protocol Activities) - Harrison
- Memorial Sloan Kettering Cancer Center (All Protocol Activities) - New York
- Memorial Sloan Kettering Nassau (Limited Protocol Activities) - Uniondale
New Jersey
- Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities) - Basking Ridge
- Memorial Sloan Kettering Monmouth (Limited Protocol Activities) - Middletown
- Memorial Sloan Kettering Bergen (Limited Protocol Activities) - Montvale
Connecticut
- Hartford Healthcare Alliance (Data Collection Only) - Hartford
Florida
- BAPTIST ALLIANCE - MCI (Data Collection Only) - Miami
Pennsylvania
- Lehigh Valley Health Network (Data Collection Only) - Allentown
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 57 participants |
| Start Date | 2022-01-14 |
| Est. Completion | 2027-01 |
| Phase | Phase 2 |
What NCT05188508 shows while recruiting
NCT05188508 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 57 participants, a relatively small participant target, below the 209-participant average among 87 other Glioma trials with a reported enrollment target (73% lower).
The record links to 1 condition, with Glioma appearing as the primary indexed condition, and to 2 interventions - of which Pembrolizumab is the first listed.
NCT05188508 lists 10 locations in 5 states (New York, New Jersey, Connecticut).
Frequently Asked Questions
What is clinical trial NCT05188508 about?
NCT05188508 is a clinical study titled "Pembrolizumab, Olaparib, and Temozolomide for People With Glioma". This study will test the safety and effectiveness of a combination of pembrolizumab, olaparib, and temozolomide to see how well these drugs work when given together in people with a glioma that either did not respond to previous treatment or came back after treatment.
What is the current status of trial NCT05188508?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 57 participants. The study started on 2022-01-14. Estimated completion is 2027-01.
What conditions does trial NCT05188508 study?
This clinical trial studies the following conditions: Glioma.
What interventions are being tested in trial NCT05188508?
The interventions under investigation include: Pembrolizumab (DRUG), Olaparib and Temozolomide (COMBINATION_PRODUCT).
Who is sponsoring clinical trial NCT05188508?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05188508 being conducted?
This trial has 10 study locations across Connecticut, Florida, New Jersey, New York, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Glioma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05188508's enrollment target sits among peer trials
57 33rd of 87 higher than 55 of 87 other Glioma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Glioma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
All-Trans Retinoic Acid (ATRA) Plus PD-1 Inhibition in Recurrent IDH-Mutant Glioma
RECRUITING · Phase 2
-
Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII
RECRUITING · Phase 2
-
Methimazole in Patients With Progressive Glioblastoma
RECRUITING · Phase 2
-
Super Selective Intra-arterial Repeated Infusion of Cetuximab (Erbitux) With Reirradiation for Treatment of Relapsed/Refractory GBM, AA, and AOA
RECRUITING · Phase 2
-
A Study Utilizing Escitalopram in Glioma Patients
RECRUITING · Phase 2
-
Proton Beam or Intensity-Modulated Radiation Therapy in Preserving Brain Function in Patients With IDH Mutant Grade II or III Glioma
ACTIVE NOT RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03521830 · 57 participants · Phase 2
Nivolumab Alone or Plus Relatlimab or Ipilimumab for Patients With Locally-Advanced Unresectable or Metastatic Basal Cell Carcinoma
- NCT03587701 · 57 participants · Phase 2
Effects of Anakinra in Subjects With Corticosteroid-resistant/Intolerant Meniere's Disease and Autoimmune Inner Ear Disease
- NCT04104126 · 57 participants · NA
Blood Flow Restriction Therapy in Achilles Injury
- NCT04703842 · 57 participants · Phase 1
Modulation of SERCA2a of Intra-myocytic Calcium Trafficking in Heart Failure With Reduced Ejection Fraction
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI